Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TYK Medicines, Inc. Class H ( (HK:2410) ) has issued an update.
TYK Medicines, Inc, a joint stock company incorporated in the People’s Republic of China, held its 2024 Annual General Meeting on June 26, 2025, where all proposed resolutions were passed. The meeting included the appointment of Dr. Zhu Xiangyang as a non-executive director and the re-appointment of Ernst & Young as auditors. The company’s shareholders showed strong support for the resolutions, indicating confidence in the company’s governance and future plans.
The most recent analyst rating on (HK:2410) stock is a Buy with a HK$31.60 price target. To see the full list of analyst forecasts on TYK Medicines, Inc. Class H stock, see the HK:2410 Stock Forecast page.
More about TYK Medicines, Inc. Class H
Average Trading Volume: 2,740,401
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$7.58B
See more insights into 2410 stock on TipRanks’ Stock Analysis page.